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ABSTRACT 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with many organ 
manifestations and characteristic immunological abnormities including a large set of 
autoantibodies with affinity for nuclear and membrane components. Autoantibodies form 
immune complexes, which cause inflammation and tissue damage in affected organs.  
Neuropsychiatric symptoms in SLE (NPSLE) are common, but clinically we lack a systemic 
strategy/protocol to follow-up or investigate these patients. Symptoms are heterogeneous, 
including both central –and peripheral nervous system manifestations. Several cytokines and 
biomarkers as well as risk factors for NPSLE have been associated with specific 
manifestations. Especially symptoms of central nervous system origin often contribute to 
serious clinical outcomes.  
The overall aim of this thesis was to provide a deeper understanding of NPSLE regarding 
clinical manifestations, to investigate the performance of potential new biomarkers and 
possible consequences that may be result from treatment with several immunosuppressive 
medications. Furthermore, to investigate two of the most common symptoms, stroke and 
seizures/epilepsy in SLE. 
       In study I, we analyzed whether the activity of the cytokines APRIL and BAFF was 
enhanced in the systemic and/or the intrathecal compartments in NPSLE patients, as 
compared to healthy and multiple sclerosis (MS) controls. We also studied the relationship 
between APRIL/BAFF and fatigue in NPSLE. Levels of APRIL in the intrathecal 
compartment were significant higher. Fatigue correlated to higher APRIL levels in NPSLE. 
        In study II, plasma and cerebrospinal fluid from NPSLE patients treated with several 
immunomodulatory medications and controls, were investigated for possible detectable John 
Cunningham virus (JCV) DNA occurrence. None of these samples showed detectable JCV 
levels. 
         In study III, we investigated the distribution of ischemic stroke subtypes in SLE 
patients, and classifying them according the system Trial of Org 10172 in Acute stroke 
Treatment (TOAST) with possible association with STAT4 and HLA-DRBI risk genotypes. 
The anti-phospholipid Syndrome (APS) and cardiovascular genes (CE) play important roles 
in ischemic stroke. Patients with stroke in APS/other determined etiology (OE) were also 
younger compared with other subgroups. The STAT4 genotype associated specifically to 
ischemic stroke in both APS/OE and CE subtypes.  
 
 
           In study IV, we report that the prevalence of classified seizures and epilepsy in SLE is 
11.5%, and the majority of defined epilepsy occurs as a focal epilepsy. APS was more 
common in patients with epilepsy compared to epilepsy-free SLE patients with or without 
NPSLE. Cerebrovascular disease was highly significantly more common. In 50% of patients 
with epilepsy no etiology other than SLE was detected.   
In conclusion, we have confirmed the importance of cytokines APRIL/BAFF in SLE, 
also detected in NPSLE in CSF. JCV DNA levels were not detectable in plasma or 
cerebrospinal fluid for the patients investigated in this study. Furthermore, patients with 
ischemic stroke seem to have association with APS or CE occurrence. Patients with defined 
epilepsy in SLE had mostly focal seizures. Cerebrovascular disease is common, and for about 
half the epilepsy cases we cannot determine any other etiology than autoimmune disease, 
SLE. Collectively, these findings support the notion of a multifaceted involvement of the 
nervous system in SLE. 
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1.  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 
1.1. BACKGROUND 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with several organ 
manifestations and characteristic immunological abnormalities including a large set of 
autoantibodies (1-4). SLE mainly affects females with peak incidence between the ages of 15 
to 40 and a male-to-female ratio of approximately 1: 9. However, SLE can also be diagnosed 
in young children and in the older population. The worldwide prevalence is estimated to be 3-
207/100 000 and in Sweden 46-85/100 000 (5-7). The prevalence varies with race, ethnicity 
and socioeconomic status (5, 8-9). In order to classify as SLE the patient needs to fulfil four 
or more of the eleven criteria, based on the 1982 American College of Rheumatology (ACR) 
revised criteria for classification (10) that include 9 clinical and 2 immunological criteria. 
However, these criteria are made to classify patients in clinical studies. There are presently no 
diagnostic criteria and thus doctors can diagnose SLE even if the criteria are not fulfilled. 
Neurological manifestations and neuropsychiatric symptoms are common and occur 
in approximately 50-90%, depending on definition. In general, neurological presentations are 
very heterogeneous and they include 19 Neuropsychiatric Lupus Erythematosus (NPSLE) 
syndromes as defined by the ACR. These syndromes affect both the central (CNS) and 
peripheral nervous systems (PNS) and they also include psychiatric manifestations (11, 12). 
One of the original 11 ACR classification criteria is neurological and includes the symptoms 
epilepsy or psychosis.  
In 2012 the Systemic Lupus International Collaborating Clinics (SLICC) group 
proposed new classification criteria for SLE. These criteria have been extended with regard to 
NPSLE symptoms and include mononeuritis multiplex, myelitis, peripheral or cranial 
neuropathy and acute confusional states in addition to seizures and psychosis (13). 
Involvement of the central nervous system (CNS) is generally associated with poor prognosis 
in SLE (14-16). 
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1.2. CLINICAL FEATURES AND CLASSIFICATION OF SLE 
The clinical manifestations are heterogeneous and presentations may differ during the course 
of SLE. In general, the disease course can be described as relapsing-remitting, chronic active 
or as a quiescent chronic active condition (17). The most frequently affected organs at any 
time are joints (arthritis/arthralgia) and skin with photosensitivity, discoid lupus or malar 
rash. Further, 30-40% are affected with nephritis, 40% with serositis presenting either as 
pericarditis or pleuritis. Symptoms of SLE can be mild and limited to only a few organs, but 
disease flares can also be aggressive with involvement of several organs simultaneously.  
According to the revised criteria for SLE by Tan 1982, 11 criteria are used to define 
SLE. There are 9 clinical or routine laboratory criteria: malar rash, discoid rash, 
photosensitivity, oral ulcers, arthritis, serositis, renal disorder, neurological disorder or 
hematologic disorder, immunologic disorder or detectable antinuclear antibodies (ANA). 
Additionally, there are two immunological criteria including: 1) antibodies to double stranded 
DNA (anti-dsDNA) or anti-Smith (anti-Sm) antibodies, positive lupus erythematosus (LE) 
cell staining or 2) an abnormal titer of ANA by immunofluorescence. A definite SLE 
classification can thus be established if the patient has presented at least four of the eleven 
criteria. Table 1. Antibodies to double stranded DNA 
Severe fatigue is a common and disabling symptom in SLE. It has also been reported 
by patients with chronic inflammatory rheumatic disease, as well as for patients with multiple 
sclerosis (MS) (18, 19). However, it is not defined by the ACR as a clinical feature in SLE or 
in NPSLE. 
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Table 1.  The 1982 revised criteria for classification of systemic lupus erythematosus*  
 
Criteria Definition 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, 
tending to spare the nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling 
and follicular plugging; atrophic scarring may occur in older 
lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient 
history or physician observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed 
by a physician 
5. Arthritis Non-erosive arthritis involving 2 or more peripheral joints, 
characterized by tenderness, swelling, or effusion 
6. Serositis Pleuritis - convincing history of pleuritic pain or rub heard by a 
physician or evidence of pleural effusion or Pericarditis -
documented by ECG or rub or evidence of pericardial effusion 
7. Renal disorder Persistent proteinuria greater than 0.5 grams per day or 
greater than 3+ if quantitation not performed. Cellular casts - may 
be red cell, hemoglobin, granular, tubular, or mixed 
8. Neurological 
disorder 
Seizures - in the absence of offending drugs or known metabolic 
derangements, e.g., uremia, ketoacidosis, or electrolyte 
imbalance Psychosis - in the absence of offending drugs or 
known metabolic derangements, e.g., uremia, ketoacidosis, or 
electrolyte imbalance 
9. Hematologic 
disorder 
Hemolytic anemia-with reticulocytosis. Leukopenia-less than 
4,000/mm3 total on 2 or more occasions OR Lymphopenia-less 
than 1 ,500/mm3 on 2 or more occasions or Thrombocytopenia-
less than 100,000/mm3 in the absence of offending drugs 
10. Immunologic 
disorder 
Positive LE cell preparation Anti-DNA: antibody to native DNA 
in abnormal titer Anti-Sm: presence of antibody to Sm nuclear 
antigen False positive serologic test for syphilis known to be 
positive for at least 6 months and confirmed by Treponema 
pallidum immobilization or fluorescent treponemal antibody 
absorption test An abnormal titer of antinuclear antibody 
11. Antinuclear 
antibody (ANA) 
 
An abnormal titer of antinuclear antibody by immunofluorescence 
or an equivalent assay at any point in time and in the absence of 
drugs known to be associated with “drug-induced lupus” 
syndrome 
 
* The proposed classification is based on 11 criteria. For the purpose of identifying patients in 
clinical studies, a person shall be said to have systemic lupus erythematosus if any 4 or more of the 
11 criteria are present, serially or simultaneously, during any interval of observation (10). 
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1.3. AUTOANTIBODIES IN SLE 
Autoantibodies play a central role in SLE, which has been proposed to be the autoimmune 
condition with the largest number (>100) of detectable autoantibodies. These include 
autoantibodies that target nuclear antigens, cytoplasmic antigens, cell membrane antigens, 
phospholipid-associated antigens, blood cells, endothelial cells, nervous system antigens, 
plasma proteins, matrix proteins and miscellaneous other antigens. The targets of these 
autoantibodies, the autoantigen IC properties, autoantibody frequencies, as well as clinical 
associations, and correlation with disease activity have previously been described (20, 21). 
Anti-nuclear antibodies (ANA) are present in 95-99% of SLE patients and antibodies 
against double-stranded DNA (anti-dsDNA) are present at any time in about 50-70%, and 
they have been shown to increase just prior to SLE onset and they are often positive in 
nephritis patients (22). Certain autoantibodies have been connected with clinical features of 
SLE. For example, anti-ribosomal P (anti-ribo P) antibodies have been linked with psychosis 
(23) and anti-Smith (anti-Sm) antibodies with milder renal and CNS disease, as well as with 
relapse of SLE. Other antibodies such as Sjögrens syndrome (Antigen- A and B) -associated 
anti- Ro (SSA), and anti-La/SSB are associated with secondary Sjögren´s syndrome, 
lymphopenia and a milder disease course while anti-C1q are associated with nephritis. 
Furthermore anti-histone antibodies have been reported in some cases of drug-induced lupus 
(23).  
 
1.3.1 Antiphospholipid antibodies (aPL) and APS syndrome 
The presence of aPL, a heterogeneous group of autoantibodies are associated with increased 
risks of thrombotic events in SLE and in the general population. These antibodies are thus 
more commonly detected in patients with a variety of vascular events. A large international 
study based on 120 full-text papers, though the majority were published before 1 reported the 
following frequencies: 13.5% in patients with stroke, 11% in myocardial infarction (MI), 
9.5% in deep venous thrombosis (DVT) and 6% among women presenting with pregnancy 
morbidity (24). 
The antiphospholipid antibody syndrome (APS) is defined by the presence of 
antibodies against cardiolipin of IgG or IgM isotypes (IgG aCL, IgM aCL) or antibodies 
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against phospholipid binding cofactor ß₂glycoprotein-I (GPI) of IgG or IgM isotypes (IgG 
anti-ß₂GPI, IgM anti-ß₂GPI) or positivity in the functional lupus anticoagulant (LA) test. One 
or more thrombotic (venous, arterial-or small vessel) event in any tissue or organ, and/or 
pregnancy-related morbidity are needed (24-26) to classify for the clinical APS criterion. At 
least one clinical criterion as well as a minimum of two positive tests at least 12 weeks apart 
are required for a confirmed APS diagnosis (27). 
APS was first described in patients with SLE, i.e. secondary APS, but it is now 
regarded as a separate entity. When APS occurs in the absence of other autoimmune 
disorders it is referred to as (primary APS). The definition is the same for primary and 
secondary APS. 
 
 
1.4. THE IMMUNE SYSTEM 
 
A vital function of the immune system is to defend the body from invasion by bacteria, 
viruses and parasites, but it is also involved in other important functions such as repair after 
tissue injury and cancer cell surveillance. At a very basic level, the immune system can be 
subdivided into two parts; natural/innate and specific/adaptive immunity. 
The innate system consists of mechanical barriers such as skin and mucosa, 
phagocytic cells of the myelomonocytic lineage (macrophages, dendritic cell, neutrophils and 
natural killer (NK) cells) and serum constituents such as complement proteins and cytokines. 
The innate immune system acts by recruiting immune cells to sites of infection or damage 
and producing cytokines and other mediators of inflammation. Activation of antigen 
presenting cells (APCs) and the complement cascade will also act as a bridge to the adaptive 
arm of the immune system.  
The adaptive immune system consists mainly of T and B lymphocytes, which 
represent the two major subdivisions, humoral and cell-mediated immunity, respectively. The 
humoral part consists of B cells that have antigen presenting properties and produce 
antibodies. Further maturation of B cells will lead to long-lived plasma cells, which are the 
main source of antibodies/immunoglobulin (Ig) molecules. The cell-mediated arm comprises 
T cells with cytotoxic or regulatory capacity.  
T lymphocytes can be further divided into major subsets T-helper (CD4+) and 
cytotoxic (CD8+) cells. However, additional T cell populations include also other types of 
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cells, such as regulatory T cells that are important for regulation of adaptive immune 
responses. Based on the types of cytokines they produce, CD4+ T-helper cells can be 
classified into additional phenotypes including T helper 1 (Th1) and T helper 2 (Th2), T 
helper 17 (Th17) and T regulatory cells (Treg). Differentiation into either of these two 
phenotypes leads to preferential secretion of certain signature cytokines. Th1 cells secrete 
interferon-γ (IFN-γ), interleukin 2 (IL-2), interleukin 12 (IL-12), and tumor necrosis factor-α 
(TNF-α), which promote cell-mediated responses. Interleukins 4, 5, 9 and 10 (IL-4, 5, 9, 10) 
instead are secreted by Th-2 cells and promote humoral or allergic responses. Th17 cells 
secrete interleukins-17, -21 and -22 (IL-17, -21, -22) and are believed to be of importance for 
mediating tissue inflammation including autoimmune disease. Tregs play an important role 
for mediation of immune tolerance and controlling immune responses so that they do not go 
out of control, which is mediated by secretion of cytokines such as interleukin -10 (IL-10) 
and transforming growth factor-ß (TGFß). 
The adaptive immune system is different from the innate immune system in that it can 
learn to recognize (adapt) and mount a very strong immune response against distinct antigens. 
Unfortunately, antigen recognition may cross-react with self-peptides or other altered self-
molecules and thus create the basis for autoimmune diseases. 
 
1.4.1. The complement system 
The complement system has a protective function in our immune system. It consists of 
plasma proteins and the activation of one component leads to a cascade of reactions. The 
classical, mannose-binding lectin and alternative complement pathways make up this system, 
each of them utilizing specific chemical functions. All lead to formations of enzymatic 
complexes (C3 and C5) and further reactions that attract white blood cells and form a 
cytotoxic membrane- attack complex (MAC).  
The classical pathway is mainly interactive with complement component C1q and IgG 
and IgM antibodies. The complement system has many biological functions. It facilitates 
phagocytosis and clearance of immune complexes (ICs) and dying cells, and it also attracts 
inflammatory cells to sites of complement activation. 
Typical findings in SLE are low serum concentrations of complement C1q, C3 and 
C4, mainly during flares (28). Furthermore, genetic C1q deficiency is a rare but strong risk 
factor for SLE. Individuals with genetic complement deficiencies, e.g. of C1q, C2 and C4, are 
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strongly predisposed to develop SLE (29). These findings may contribute to our 
understanding of up-regulation of the type I IFN system seen in SLE patients (28).  
 
  
1.4.2. The immune system and SLE 
In SLE a central immunologic disturbance is the excessive production of autoantibodies that 
induce damage via several mechanisms. Autoantibodies target self-molecules that are present 
in the nucleus, the cytoplasm and on cell surfaces. Antibodies together with their antigens and 
complement proteins form immune complexes, which are trapped, or possibly formed in 
tissues, where they can activate complement and cause inflammation and damage. The 
inflammatory state leads to further immune cell abnormalities and dysregulation that involves 
B cells, T cells and cells of the monocyte lineage. Both innate and adaptive immunity are 
highly involved. 
Increased systemic inflammation can be detected in patients with SLE. However, 
classical measures of inflammations, such as C-reactive protein are not good markers of SLE 
disease activity. Rather, high levels of multiple pro-inflammatory cytokines in peripheral 
blood have been reported in active SLE disease.  
Type I interferons (IFN), including interferon-α (IFN- α) have been demonstrated to 
correlate both with disease activity and severity, and this is a key cytokine in lupus. Type I 
IFNs have also being associated with vascular disease in SLE (30-32). TNF-α is another 
cytokine that together with its soluble receptors 1 and 2 reflects disease activity (33,134). The 
complement system is also important in SLE, where peripheral blood levels of several 
complement proteins are depressed due to consumption during more active disease. This is 
especially common during active nephritis (29, 34).  
 
1.4.3. B-cell efficiency- BAFF and APRIL 
B cells require signals from several sources for their maturation from precursor cells and for 
further developing to effector cells. Two closely related cytokines belonging to the tumor 
necrosis factor (TNF) family are involved in various human autoimmune conditions (35). 
High levels of both B-cell activating factor (BAFF) and a-proliferation-inducing ligand 
(APRIL) have been demonstrated in patients with SLE and in other autoimmune conditions 
such as rheumatoid arthritis and Sjögren’s syndrome (36-38).  
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BAFF, also known as TALL-1, THANK, Bly S, zTNF4 and TNFSF13, and APRIL, 
also known as TRDL-1, are both linked to B-cell survival, Ig isotype switching, and B-cell 
antigen presentation (39-41). They are present in the circulation as soluble trimeric ligands, 
but BAFF can also be detected as a membrane-bound protein (40).  
Both of these cytokines bind to two receptors, B-cell maturation antigen (BCMA) and 
transmembrane activator (TACI), BAFF also separately binds to BAFF-R, and thereby 
regulates B-cell survival. Figure 1. 
 
 
Figure 1. 
 
 
 
 
BAFF and APRIL were highlighted at the time of our study, since clinical trials of a new 
human anti-soluble BAFF monoclonal antibody, Belimimab, were ongoing. Efficacy in lupus 
patients has since been demonstrated. Belimimab is now registered for treatment of SLE and 
is has been shown to reduce both disease activity and fatigue (42, 43). 
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1.4.4. Genetics 
More than 60 genetic variants have been linked to risk of SLE. The most strongly associated 
genetic region is the HLA region, located on chromosome 6, which contains many genes of 
importance for the immune system and for autoimmunity including those encoding for the 
major histocompatibility class I and class II chains. Some of the identified SLE susceptibility 
genes located elsewhere in the genome are linked to interferon signaling, such as interferon 
regulatory factor 5 (IRF5) and signal transducer and activator of transcription 4 (STAT4), 
both of which have been repeatedly confirmed to be associated with SLE (44-46). 
Additionally, although less common, persons with genetic deficiencies of complement 
proteins involved in the classical complement activation pathway are prone to develop SLE 
(29, 47).  
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2.  CLINICAL SYMPTOMS IN NPSLE 
Neurological symptoms in SLE are common and may have multiple causes. Of the 19 
NPSLE case definitions by ACR (11) 12 are syndromes or manifestations from the CNS: 
aseptic meningitis, cerebrovascular disease, demyelinating syndrome, headache, movement 
disorder, myelopathy, seizure disorder, acute confusional state, anxiety disorder, cognitive 
dysfunction, mood disorder and psychosis, while 7 involve the PNS; Guillain-Barré, 
autonomic disorder, mononeuropathy, myasthenia gravis, cranial neuropathy, plexopathy and 
polyneuropathy. PNS symptoms are less common than CNS involvements. Table 2.   
Involvement of the CNS in SLE is potentially severe, but still in most cases a treatable 
condition (48). Unfortunately, there is a lack of validated biomarkers for CNS involvement 
and neuroradiological findings may be non-specific. The fact that opportunistic infections, 
sometimes a consequence of immunosuppression, may mimic NPSLE symptoms further 
complicates the diagnostic work-up (49-53). Several cytokines have been suggested to be 
increased during fatigue in SLE, but studies so far have not provided evidence for association 
to disease activity or other markers of disease or inflammation (54). 
 
Table 2.  19 NPSLE syndromes as defined by the American College of Rheumatology 
 
 
     Central Nervous System  
▪ Aseptic meningitis 
▪ Cerebrovascular disease 
▪ Demyelinating syndrome  
▪ Headache (including migraine and  
idiopathic intracranial hypertension) 
▪ Movement disorder (chorea) 
▪ Myelopathy 
▪ Seizure disorder 
▪ Acute confusional state 
▪ Anxiety disorder 
▪ Cognitive dysfunction 
▪ Mood disorder 
 
     Peripheral Nervous System  
▪ Acute inflammatory demyelinating 
 polyradiculopathy (Guillain-Barré) 
▪ Autonomic disorder 
▪ Mononeuropathy, single or  
multiplex 
▪ Myasthenia gravis 
▪ Cranial neuropathy 
▪ Plexopathy 
▪ Polyneuropathy 
 
Extensive efforts have been made to better understand the underlying pathological 
mechanisms for neurological symptoms in NPSLE, and several candidate biomarkers have 
11 
 
been suggested (55). However, many issues remain to be resolved and it is likely that several 
mechanistic pathways are involved and probably overlap. Neuropathological studies, by 
necessity performed in severe and dramatic clinical manifestations of CNS involvement, 
often demonstrate ischemic changes in small vessels such as cortical microinfarctions and a 
general vasculopathy with degenerative or proliferative changes generally (23). Reductions in 
cerebral and corpus callosum volumes and atrophy have been associated with disease 
duration and the history of CNS involvement and cognitive impairment. Furthermore, the 
total corticosteroid dose and the presence of aPL have not shown association to brain atrophy 
(56, 57). Macroscopic infarctions are less common. Embolism often arises from the heart, 
due to heart valve involvement, usually more discrete but sometimes in accordance with 
Libman-Sacks endocarditis (58-61). Both inflammatory infiltrates and destruction of blood 
vessel walls may occur, but necrosis indicative of vasculitis is rarely observed.  
NPSLE is associated with systemic-and brain-specific antibodies (62). A recent meta-
analysis of serum and CSF autoantibodies by Ho et al (51) reported that NPSLE patients, 
mainly those with CNS symptoms, tend to have higher levels of aPL including aCL and LA, 
as well as, anti-ribo P abs and anti-neuronal abs compared with SLE patients without 
neuropsychiatric symptoms. This was especially evident for patients with psychiatric 
conditions, cognitive impairment, cerebrovascular disease and seizures. Additionally, brain-
specific abs such as anti-ganglioside, anti-glial fibrillary acidic protein, anti-lymphocytotoxic 
and anti-NMDA as well as anti-neuronal abs were mainly encountered in neuropsychiatric 
conditions. Neuropathy, psychosis and seizures have been reported to associate with anti-
microtubule protein 2 antibodies leading to changes in neuron morphology (63). 
One possible mechanism for vascular occlusion and injury by pathogenic antibodies is 
a disrupted blood brain barrier (64). Antibodies can mediate neurological injury by reacting 
against neuronal, astroglial or endothelial cells (23, 65-67). According to a more recent 
hypothesis, subtypes of N-methyl D-aspartate (NMDA) receptors may become targets for 
cross-reactive anti-DNA antibodies and the neuronal excitations, by way of excessive 
activation, may lead to neurocognitive disturbances and eventually to brain atrophy (67-70). 
aPL occur in 30-40% of SLE patients (71) and are associated with thrombotic and/or obstetric 
manifestations and seizures (30, 64, 72, 73). Furthermore, interferon-α (IFN-α) and other type 
I interferons have been demonstrated to correlate both with disease activity and severity and 
also have strong associations to vascular disease in SLE (22). Elevated levels of APRIL have 
also been reported in cerebrospinal fluid for SLE patients with neuropsychiatric symptoms as 
compared to controls (74).  
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Neuropsychiatric lupus erythematosus syndromes are often associated with global 
disease activity (75). Nonspecific cerebrospinal fluid (CSF) abnormalities are present in 
about 30% of patients, including elevated levels of monocytes, elevated protein levels or 
abnormalities in intrathecal production of immunoglobulins (76, 77). Levels of cytokines 
such as IL-6, -8 and -10 has been reported to be increased in the CSF of individuals with 
neurolupus compared with non-CNS lupus (78). The electroencephalogram (EEG) changes in 
NPSLE patients are often nonspecific generalized slowing (48).  
Imaging with computed tomography (CT) may show evidence of cerebral infarction 
and hemorrhage, cortical micro-infarcts or vasculopathy and degenerative changes, and in 
chronic cases subcortical atrophy. Magnetic resonance imaging (MRI) is useful especially in 
patients with diffuse presentations. It reveals small infarcts in acute states, focal cerebral 
edema and detects myelitis better than CT. However, there are no MRI findings that are 
diagnostic of NPSLE (78, 79). Positron emission tomography (PET) has also been used to 
detect areas of disturbed cerebral circulation and metabolism (80). 
Neuropsychiatric manifestations are common in SLE and may present in the context 
of general disease activity or as isolated events. Patients often present with mixed neurologic 
and psychiatric manifestations. The prevalence of NP manifestations according to ACR case 
definitions is variable. Accordingly several studies report that from 14% to over 90% of SLE 
patients presenting with neurological or psychiatric symptoms at some time during their 
illness (78). A recent large international, multicenter prospective study reported that 40.3% of 
the patients had at least one clinical NP event and 17.4% were diagnosed with multiple events 
(81). Different results may be due to technical variations between the studies, study designs 
and selections of the patients, study populations and how the original information was 
obtained. However, the most common NPSLE symptom reported are related to CNS 
manifestations. Most frequent are intractable headaches 24% (82, 83) including mostly 
tension-type and/or migraine, cluster headache or pseudo tumor cerebri. The second most 
common manifestation is cerebrovascular disease 14.5%, including transitory ischemic 
attack, ischemic stroke, subarachnoid/intracranial hemorrhage and sinus thrombosis. Mood 
disorders with major depressive episodes, depressive features and with manic features are 
common. Cognitive disorder have been reported to occur in about 11% and seizures in 8.3%. 
Psychosis as well as anxiety disorders are fairly common symptoms. Manifestations from 
PNS are seen more seldom, except polyneuropathy and cranial neuropathy (82). According to 
a Finnish study at least one NPSLE syndrome was identified in 91% of SLE patients (84). 
Cognitive dysfunction was present in 81%, followed by headache in 54% and mood disorder 
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in 43%. Headache, cognitive dysfunction and psychiatric disorders followed by seizures are 
also reported as the most common NPSLE syndromes in other studies (12, 85). 
 
2.1. CEREBROVASCULAR DISEASE AND SLE 
Stroke is defined by rapid onset of focal neurological deficit due to infarction or hemorrhagic 
vascular event lasting more than 24 hours, being the second most common cause of death 
worldwide and most common cause of neurological disability (86-89). A populations-based 
stroke register study in European countries reported an annual stroke incidences of 63-
239/100 000 with a median age of 73 years, higher rates of stroke being reported in eastern 
and lower rates in southern European countries (90), with an incidence of 144/100 000 in 
Sweden (91).  
Early risk of stroke following a transitory ischemic attack (TIA) is high; the 7-day risk 
is 8-12% and 30 day risk 18%. Traditional well-established risk factors are: age >55 years 
and male gender, hypertension, smoking, diabetes mellitus, hypercholesterolemia, atrial 
fibrillation and myocardial infarction. 
A recent population-based meta-analysis by Holmqvist et al. (92) reported that 
individuals with SLE have a two-fold increased risk of ischemic stroke compared to the 
general population and that the relative risk of stroke was highest among individuals younger 
than 50 years of age. Another large meta-analysis performed with a wider clinical material of 
rheumatic diseases reported risk of any stroke to be particularly higher for patients with 
rheumatoid arthritis and systemic lupus erythematosus (93). In a large cross-sectional study 
from our group ischemic cerebrovascular disease occurred in 12% of Swedish SLE patients 
(44). The mean annual stroke incidence in another SLE cohort was 6.45/1000 patients where 
90% had ischemic strokes and 10% hemorrhagic events. Furthermore, stroke occurred in 57% 
of SLE patients with a history of TIA (94, 95). High mortality 20-30% in SLE occurs due to 
cerebrovascular events.   
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2.1.1. Stroke subtypes according to TOAST 
The Trial of Org 10172 in Acute Stroke Treatment (TOAST) (96) criteria is the most 
commonly used for pathogenic classification of stroke cases. It is designed to classify 
ischemic strokes, and is mainly based on etiology, being defined for use in a multicenter 
clinical trial setting, TIA being excluded. Five major categories of the TOAST classification 
are as follows: large-artery atherosclerosis (LAA); cardio-embolism (CE); small artery 
occlusion (SAO); stroke of other determined cause (OC); and stroke of undetermined cause 
(UE). The sub-type definitions are based on risk factor profiles, clinical features, and results 
of diagnostic tests (97). 
A population-based prospective study for incidence, recurrence and long-time 
survival rates of ischemic stroke in European populations according to TOAST criteria, 
reported the following distributions of stroke sub-types: CE 27%, SAO 23%, LAA 13%, OE 
2% and UE 35% (97, 98). Another previous prospective study among SLE patients reported 
that the LAA was most common sub-type, in 45%, SAO occurred in 39% and CE in 9% 
followed by 7% of UE (131). 
 
 2.1.1.1. Large artery atherosclerosis (LAA) 
Patients in this category should have a history of large-artery atherosclerosis, supported by 
clinical and brain imaging findings. Typically findings for these patients include a significant 
(>50%) stenosis or occlusion of a major brain artery or branch cortical artery or in an 
extracranial artery, and history of transient ischemic attacks (TIAs) in the same vascular 
territory with symptoms of cerebral cortical impairment. Ischemic lesions located in cerebral 
cortex, cerebellum, brainstem or in subcortical areas should be greater than 1.5 cm in 
diameter as visualized by CT or MRI. 
 
2.1.1.2. Cardio-embolism (CE) 
The TOAST classification includes both high- and medium risk sources for cardio-embolism 
causes of an arterial occlusion and stroke. Clinical evidence of previous TIA or stroke in 
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more than one vascular territory or systemic embolism supports a clinical diagnosis of 
cardiogenic stroke. The patients have similar clinical and brain imaging findings as in the 
LAA group. 
 
2.1.1.3. Small artery occlusion (SAO)/lacunar 
Patients in this group should have a normal CT/MRI examination or a relevant brainstem or 
subcortical hemispheric lesion with a diameter of less than 1.5 cm. Clinical diagnosis is also 
supported if the patient has a history of diabetes mellitus or hypertension. 
 
2.1.1.4. Acute stroke of other determined etiology (OE) 
Non-atherosclerotic vasculopathies, hypercoagulable states and hematologic disorder are all 
represented in this category. According to TOAST this subgroup includes patients with rare 
causes of stroke. Patients should have clinical and CT or MRI findings of an acute ischemic 
stroke, regardless of the size or location. Diagnostic studies such as blood tests or 
arteriography should reveal one of these unusual causes of stroke. Cardiac sources of 
embolism and large artery atherosclerosis should be excluded. In our study we included all 
patients with APS and SLE, as a known multisystem disease and without evidence of these 
other conditions, in this sub-group. 
 
2.1.1.5. Stroke of undetermined etiology (UE) 
This category includes the cases of unclear etiology despite an extensive evaluation or 
insufficient evaluation. The patients with two or more potential causes of stroke, where the 
physician is unable to make a final diagnosis are included in this group. 
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2.2. EPILEPSY, SEIZURES AND NPSLE 
Seizures are a well-recognized complication (85, 99) in SLE and are suggested to be a result 
of a combination of immune, vascular, metabolic and inflammatory mechanisms. 
Furthermore, the generalized seizures have been associated with elevated levels of IgG, 
oligoclonal bands, and increased cytokine production, also with enhanced titers of anti-
neuronal antibodies (85, 100). Seizures have also been reported to be an early CNS 
manifestation (48, 101) in SLE and are in some studies also diagnosed as an isolated epilepsy 
(102). Variable frequencies and prevalence of seizure disorder are described, from 6–51% of 
adults and pediatric SLE patients (12, 82, 84, 103-106) and is reported to be more frequent in 
children. Furthermore, unprovoked seizure in MS and SLE in population-based case-control 
studies reported increased risks in both of these conditions (107). 
 
2.2.1. Definition of epilepsy 
Epilepsy has been defined as a condition characterized by recurrent (two or more) epileptic 
seizures, unprovoked by any immediate identified cause in the 1993 International League 
Against Epilepsy (ILAE) Commissions report (108). The new conceptual ILAE from 2005 
defines epilepsy as a disorder of the brain characterized by an enduring predisposition to 
generate epileptic seizures and by the neurobiological, cognitive, psychological and social 
consequences of this condition (109). 
As follow-up of this conceptual definition, the ILEA in 2014 published a report 
describing a practical clinical definition of epilepsy. In accordance to this, epilepsy is a 
disease of the brain that can be defined by any of the following conditions: (I) At least two 
unprovoked (or reflex) seizures occurring >24 h apart; (II) one unprovoked (or reflex) seizure 
and a probability of further seizures similar to the general recurrence risk (at least 60%) after 
two unprovoked seizures, occurring over the next 10 years; (III) diagnosis of 
an epilepsy syndrome (110, 111). 
Important for an epilepsy diagnosis is the distinction between unprovoked and 
provoked (acute symptomatic) seizures. A seizure provoked by a transient factor acting on an 
otherwise normal brain to temporarily lower the seizure threshold does not qualify for 
epilepsy, even if recurrent. Epileptic seizures occurring in conjunction with an SLE flare or a 
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metabolic derangement, are hence considered to be acute symptomatic and do not count as 
epilepsy. 
Epilepsy is considered to be resolved for individuals who either had an age-
dependent epilepsy syndrome, but are now past the applicable age or who have remained 
seizure-free for the last 10 years and off anti-seizure medicines for at least the last 5 years. 
ˋResolvedˊ is not necessarily identical to the conventional view of ˋremissionˊ or ˋcureˊ.  
 
2.2.2. Definitions of seizures 
The definition and classification of seizures differs from that of epilepsy. A seizure is a 
transient occurrence of signs and/or symptoms of epilepsy due to abnormal excessive or 
synchronous neuronal activity in the brain (109). The seizure presentations depend on the 
location of onset in the brain and the pattern of propagation. The seizures can further affect 
sensory, memory, cognition, or behavior. Somatosensory, auditory, visual, olfactory, 
gustatory and vestibular sensory and also more complex internal sensations that can be 
presented (109). 
Seizures are classified as either focal or generalized, the former focal involving a 
localized part of the brain whereas generalized seizures rapidly involve the whole of both 
brain hemispheres from the onset. Secondary generalized describes the condition in which a 
focal seizure from a primary focus in some part of brain spreads into both hemispheres and 
becomes generalized. This classification does not describe the etiology, prognosis or 
pathophysiology for causes of seizures or epilepsy. 
 
 
2.3. JC–VIRUS, PML and SLE 
 
Progressive multifocal leukoencephalopathy (PML) is a rare but often fatal demyelinating 
disease of the CNS caused by the polyomavirus John Cunningham virus (JCV), with a mean 
survival time of 3-6 months (112). Due to immunosuppression the virus can reactivate and 
enter the brain and infect oligodendrocytes, causing a fulminate infection, demyelination, 
PML and further pathological destruction of the brain (113). (Figures 2 and 3). The primary 
infection occurs in up to 80% of the individuals, usually asymptomatic and after infection the 
virus tend to stay latent in the kidneys, bone marrow and lymphoid tissues and glial cells. 
Both T- and B cell effector functions are required to prevent viral reactivation (114). 
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The incidence of PML in autoimmune diseases, including rheumatic diseases and 
mostly in patients with systemic lupus erythematosus has increased as a consequence of use 
of more potent immunosuppressive drugs such as biologics (rituximab, natalizumab, 
infliximab and efalizumab), methotrexate, azathioprine, cyclophosphamide and 
mycophenolate mofetil and even with a minimum of immunomodulatory treatments (115-
119). 
Figure 2. 
 
         
Pathology of progressive multifocal leukoencephalopathy (PML). (113)                                                                          
A. PML lesions affecting the superficial subcortical gray-white matter junction in the cerebral 
hemisphere. Multifocal punctate demyelinating lesions in subcortical white matter.                                                              
B. Microscopic demyelinated lesion in the white matter immediately subcortical. The cortex and 
neuronal cell bodies are in the left of the picture. 
 
Figure 3.  
 
 
Brain MR imaging of PML lesions associated with lupus and methotrexate overdose (119) 
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SLE/NPSLE is a complex condition with several immune aberrations.  In our studies 
included in this thesis I have chosen to concentrate on some important clinical 
manifestations: stroke, epilepsy, PML, biomarkers and fatigue.  
 
  
20 
 
3. AIMS OF THE THESIS 
 
The overall aim of this thesis was to provide a deeper understanding of NPSLE regarding 
clinical manifestations, potential biomarkers and pathophysiology.  
 
The specific aims of this thesis were as follows: 
 
1 To study whether APRIL/BAFF activity is enhanced in the systemic and/or the 
intrathecal compartments in neuropsychiatric SLE (NPSLE) patients compared to 
healthy controls, and to study the relationship between APRIL/BAFF and fatigue in 
neuropsychiatric SLE  
 
2 To analyze whether JCV DNA can be detected in plasma or cerebrospinal fluid (CSF) 
in a large group of patients with NPSLE treated with immunomodulatory medication. 
3 To investigate the distribution of ischemic stroke subtypes in SLE patients, classified 
according the TOAST system (Trial of Org 10172 in Acute stroke Treatment) and the 
association of stroke subtypes with the SLE risk genotypes; STAT4 and HLA-DRB1. 
 
4 To determine the prevalence and classify seizures and epilepsy among patients with 
SLE and investigate the relationship between epilepsy and other manifestations of 
neuropsychiatric SLE.  
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4.  MATERIALS AND METHODS 
4.1. SUBJECTS AND STUDY DESIGN (I-IV) 
The patients included in our studies are mainly from a cohort, which now comprised about 
440 SLE patients who fulfilled criteria for SLE (10, 11) and attending the Rheumatology 
Clinic at the Karolinska University Hospital. (Figure 3). During time of our studies, the 
rheumatologist added new patients to this Hospital-based cohort from 1996 to 2012. Studies I 
and II were cross-sectional and the SLE-patients were referred to the neurology clinic for 
clinical investigation because of NPSLE symptoms. In this thesis we utilized blood and 
cerebrospinal fluid that were kept frozen at -70˚C in our in-house biobank. MRI and/or CT 
scans of the brain, EEG and other neurophysiological investigations were performed 
depending on the clinical presentation. All the patients in study IV were from this cohort. In 
study III the patients were included from the cohorts in Karolinska Solna (N=380), Uppsala 
(N=131) and from Lund (N=154). Studies III and IV had a retrospective design. The matched 
control samples used in studies I and II were from non-inflammatory neurological patients, 
mostly tension headache and in study I samples from relapsing remitting Multiple sclerosis 
(RRMS) patients were included. 
 
 
Figure 3. Study design 
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All studies included were approved by the regional Ethics Committee and written informed 
consent was obtained from all study participants. 
 
Paper I 
Twenty-eight patients with neurological manifestations of SLE were included. APRIL and 
BAFF in paired plasma and CSF samples from NPSLE patients were quantified using a 
commercial ELISA kit, thirteen RRMS patients and seventeen OND patients acting as 
controls. Quantitative PCR was performed for APRIL and BAFF mRNA respectively for 
CSF and PB. The Fatigue Severity Scale (FSS) was used to measure the degree of fatigue. 
Paper II 
Plasma and/or CSF samples from 71 NPSLE patients and 58 control cases were analyzed. 
JCV DNA was analyzed using a quantitative PCR method. Paired CSF and plasma samples 
were obtained from 49 NPSLE patients and 44 of the control patients. At sampling ongoing 
medication were documented: corticosteroids (n=51), Hydroxychloroquine (n=22), 
Azathioprine (n=15), Methotrexate (n=3), Mycophenolate mofetil (n=3), Rituximab (n=3), 
Cyclosporine (n=1), Immunoglobulin (n=1), none for Cyclophosphamide, Chlorambucil or 
Reumacom. One of the patients had previously undergone autologous hematopoietic stem 
cell transplantation and plasmapheresis. Five patients had no treatment. 
Paper III 
Among 665 genotyped SLE patients from three large cohorts we identified 69 patients with 
stroke. The medical charts were reviewed and brain, cardiac and vascular imaging at the time 
of stroke was reinvestigated. The 56 ischemic stroke cases were possible to evaluate and 
categorize according to the TOAST subtypes. Evaluators were blinded to genotype. 
Association with STAT4 and HLA-DRB genotypes were explored. In the genetic 
comparisons the controls were either SLE patients free from previous ischemic 
cerebrovascular disease or general population controls. 
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Paper IV 
The WHO epilepsy screening questionnaire was sent to all of 440 patients who were still 
alive or not lost during the follow-up. A totally of 368 questionnaires were dispatched, the 
patient who positive screened cases were offered neurological examination. The medical 
records of the patients were reviewed. Seizures were classified and NPSLE symptoms 
documented according to ACR nomenclature. Occurrence of autoantibodies and the 
antiphospholipid syndrome were recorded. 
 
4.2. CLINICAL INSTRUMENTS – QUESTIONNAIRES 
 
In paper I we used the fatigue severity scale, the most frequently used scale for SLE and MS 
patients for the assessment of subjective fatigue. It has high reliability, validity and internal 
consistency. It comprises a nine-item scale scored from one to seven; the mean value of the 
answered questions results in the final score (range 1-7) (18).  
In paper IV we used the WHO screening questionnaire of epilepsy (WHO, Epilepsy 
management at a primary health level (WHO; 2000; Geneva; 2000) to discern possible signs 
or symptoms of epilepsy. This questionnaire includes thirteen statements to answer ˋyesˊ or 
ˋnoˊ; one positive answer is required for further investigation. Seizure disorders were 
classified according to the proposal by the International League against Epilepsy (ILAE) 
including the guidelines for Epidemiologic studies on Epilepsy (108-110). Acute 
symptomatic seizures were defined as suggested by the ILAE Task Force (120). 
 
4.3. LABORATORY MEASUREMENTS 
 
4.3.1. Cerebrospinal fluid and routine laboratory parameters 
In papers I and II the CSF and blood work-up performed were as a part of routine analysis. 
Abnormal CSF parameters included a monocyte cell count > 5 cells/µL, IgG index >0.7 or 
signs of blood-brain barrier dysfunction. The assays were conducted at the Department of 
Clinical Chemistry, Karolinska University Hospital. Prepared and paired CSF and plasma 
samples were stored and kept frozen at -70⁰C in our biobank at the Neurological Clinic until 
use. 
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4.3.2. Autoantibodies (I-IV) 
Papers I and II. Autoantibody tests were performed as routine analyses at the Department of 
Clinical Immunology, Karolinska University Hospital. Antibodies to nuclear antigens (ANA) 
were analyzed on HEp-2 cells (Immunoconcepts, Sacramento, CA, USA). Antibodies to 
Sjögren’s syndrome A/B (SSA/SSB), Sm, and RNP were analyzed using an ANA-profile 
enzyme-linked immunosorbent assay (ELISA; Pharmacia Diagnostics, Uppsala, Sweden), 
Innolia Immunoblot (Innogenetics, N.U. Ghent, Belgium), and Auto Immunodiffusion 
(Immuno Concepts).  
For paper III anti-dsDNA was assayed by ELISA dsDNA (Pharmacia Diagnostics, 
Uppsala, Sweden). Autoantibodies against cardiolipin (IgG and IgM) and ß2glycoprotein I 
(ß₂GPI, IgG) were analyzed by ELISA (Orgentec, Mainz, Germany), in frozen serum 
samples at the time of inclusion into the genetic studies, i.e. after the stroke event. 
For paper IV the antibodies to specific nuclear antigens (dsDNA, SSA/Ro52, 
SSA/Ro-60, SSB, Sm) and phospholipids cardiolipin (IgG, IgM) and ß2glycoprotein I 
(IgG, IgM) were analyzed using a multiplexed bead technology (Luminex) using 
BioPlex 2200 system (Bio-Rad, Hercules, CA, USA) according to the specifications of 
the manufacturer. The cut-off for anti cardiolipin (aCL) and antiß2-glycoprotein 1 
(aß2GP1) fulfill the 99
th percentile as described (121). LA was determined using a 
modified Dilute Russel Viper Venom method (Biopool, Umea, Sweden) using Bioclot 
lupus anticoagulant.   
The anti-phospholipid syndrome (APS) was defined by the presence of anti-
phospholipid antibodies (a PL) and one or more thrombotic (venous, arterial or small 
vessel) episodes in any tissue or organ, or pregnancy-related morbidity. At least one 
clinical and one laboratory criterion (minimum of two positive tests taken at least 12 
weeks apart) are required for APS classification (27). 
 
4.3.3. Quantification of APRIL and BAFF by ELISA PCR 
Levels of soluble APRIL and BAFF in paired plasma and CSF samples were quantified using 
a human APRIL ELISA kit (BenderMedSystem in Vienna, Austria) and a human BAFF 
ELISA kit (R&D Systems, Abingdon, UK).  Quantitative PCR was performed for APRIL and 
BAFF mRNA respectively, for CSF and PB. APRIL primers were custom-designed by 
Applied Biosystems. BAFF primers and the endogenous control glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH) were purchased from Applied Biosystems. APRIL and BAFF 
mRNA levels were quantified and normalized for GAPDH expression (122, 123). For more 
details, see the section for subjects and methods in paper I. 
 
4.3.4. JCV PCR analysis  
For paper II total DNA was extracted from 200 ml of plasma or CSF using M48 Blood and 
Tissue Midi Kit (Qiagen, Hilden, Germany) in combination with the M48 Biorobot (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol. DNA obtained from the plasma 
samples was diluted in a volume equal to the starting volume, while DNA obtained from the 
CSF samples was adjusted to a ﬁnal volume of 50 µl. Quantiﬁcation of JCV DNA was 
performed by RealTime PCR (qPCR). The speciﬁc JCV primers and probe were designed to 
amplify a part of the VP 2 region (forward primer 50 CTGAACC 
AAAAGCTACATAGTAAGTAATGT-30, reverse primer 
50CTAGTCCCCCAAAAGTGGAA-3, probe 50FAM-AGGTTCATGGGTGCCGC-30 
MGB). The detection limit for JCV DNA in plasma was 200 copies/ml, and corresponding 
limit for CSF was 50 copies/ml. (124, 125). For further details, please refer to paper II. 
 
4.3.5. Genotyping 
In paper III, standard procedures were used to extract DNA from blood samples.     
Genotyping: The genotypes for SNP rs10181656 in intron 3 of the STAT4 gene were 
determined using the Goldengate assay (Illumina Inc., San Diego, CA, USA) (126). The 
genotype call rate was 97.0 % and the reproducibility 100% as determined by duplicate 
genotyping of 17 samples. An additional, partly overlapping, set of 156 subjects had 
previously been genotyped using the SNPstream system (Beckman-Coulter Inc., Fullerton, 
CA, USA). The concordance between the two methods was 100%. The genotypes of the SNP 
rs10181656 in controls conformed to Hardy-Weinberg equilibrium (p > 0.05). Patients were 
included in the genetic studies on average of 7.8 years after their first stroke episode (44, 
127).       
 HLA-DRB1 genotyping was performed by sequence-specific primer PCR assay 
(SSP-PCR) (DR low-resolution kit; Olerup SSP, Saltsjöbaden, Sweden) and the PCR 
products were loaded into 2% agarose gels for electrophoresis. An interpretation table was 
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used to determine the specific genotype according to the manufacturer’s instructions (126). 
The HLA-DRB1 allelic groups studied were DRB1*01, DRB1*03, DRB1*04, DRB1*07, 
DRB1*08, DRB1*09, DRB1*10, DRB1*11, DRB1*12, DRB1*13, DRB1*14, DRB1*15 
and DRB1*16.  
 
4.3.6. Statistical analyses 
Statistical analyses were performed using non-parametric Wilcoxon signed ranks test, and 
correlations between demographic variables were analyzed with Spearman's rank test 
(Graphpad Prism 5.0, San Diego, CA). A probability value less than 0.05 was considered 
statistically significant in paper I. Standard descriptive statistics were used for presentation of 
the categorical variables and were summarized as counts and percentages. Continuous 
variables were expressed as median and interquartile range in papers I, II and IV.  In paper IV 
statistical analyses were performed by calculating correlations between demographic 
variables and analyses between the groups were performed with Dunn’s multiple comparison 
and Fisher’s exact t-test using Graphpad Prism 5. A p-value <0.05 was considered 
statistically significant. In paper III clinical patient characteristics and allele frequencies were 
compared between groups with chi-squared tests or Fisher’s exact test, depending on 
numbers of investigated individuals. Odds ratios (OR) and 95% confidence intervals (CI) 
were calculated from 2x2 contingency tables. Continuous variables were analysed using 
Mann-Whitney U-test or students T-test, depending on variable distribution. A p-value <0.05 
was considered significant. Bonferroni corrections, based on 24 tests regarding STAT4 and 
96 tests for HLA-DRB1 calculations, yielded p<0.002 for STAT4 and p<0.0005 for HLA-
DRBI as corresponding significant p-values. Data processing was performed using JMP 
software (SAS Institute Inc. Carey, North Carolina). 
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5.  RESULTS AND DISCUSSION  
5.1. PAPER I   
BAFF and APRIL are cytokines suggested to be of importance for autoimmune diseases. At 
the time our study was performed, a BAFF blocking antibody, Belimumab had shown 
efficacy in clinical trials in lupus patients. We aimed to investigate these B-cell survival 
molecules in the intrathecal and systemic compartments in SLE patients with neurological 
symptoms compared with controls. 
NPSLE patients had higher levels of APRIL in CSF as compared to OND (p<0.01). 
No corresponding increase in APRIL mRNA levels was detected in CSF-MC. BAFF levels in 
plasma were higher in NPSLE than in OND (p < 0.001). BAFF mRNA expression in PBMC 
was also higher in NPSLE patients than in controls (p < 0.05). FSS score levels in NPSLE 
patients was with median 5.56 (range 4.56-6.67) and correlated significantly with APRIL 
levels in CSF (p<0.05).       
             Three patients displayed very high levels of APRIL in CSF and they all scored high 
on the FSS questionnaire (6.63–7.00), one of them having an acute exacerbation of NPSLE 
with cognitive symptoms and impaired vision at the time of sampling. Four patients displayed 
very high CSF BAFF levels, two of these being investigated during an acute exacerbation of 
NPSLE. Three of these four patients had pathological alterations in BBB function together 
with high levels of plasma BAFF. In two of the three patients with BBB dysfunction, a high 
level of BAFF mRNA expression in PBMC was noted.                                                                                                        
Nearly half of the patients received immunosuppressive treatment such as rituximab, 
azathioprine, methotrexate, cyclophosphamide, and anti-malarias, at the time of sampling.  
A total of four had acute neuropsychiatric manifestations requiring hospitalization at the time 
of sampling. Headache was the most common symptom (57%). Cognitive symptoms were the 
second most common symptom (36%), followed by mood disorder (25%).  
In conclusion, we found a correlation between higher scores in FSS with high APRIL 
levels in CSF for NPSLE patients. Higher BAFF levels in plasma and in peripheral blood for 
NPSLE patients compared to controls. Higher levels of APRIL in CSF for NPSLE were 
recorded compared to OND. These results indicate that intrathecal immunological activity 
contributes to fatigue in SLE. Our study has limitations, as it is a small study. We might also 
include patients with SLE without any neurological symptoms as controls. To get more 
power we should have had a more clear hypotheses from the beginning.  
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5.2. PAPER II 
There are several clinical case reports of PML, a potentially fatal disease, in SLE patients, 
both in association with newer biologic immunosuppressive or immunomodulatory 
treatments, but also among patients treated with conventional disease-modifying agents. PML 
as a risk with newer biologicals became highlighted in 2004, when three of 3000 patients 
with MS/Crohn's disease treated with natalizumab developed PML due to reactivation of 
asymptomatic and latent JCV infection with subsequent development (128, 129).   
Our intention for this study was to test the hypothesis that NPSLE patients who were 
treated with different types and duration of immunosuppressive medication would display 
reactivation of JCV and that detection of JCV in the systemic circulation or in CSF should in 
that case be possible. 
  CSF (n=69) and plasma (n=51) samples from 71 NPSLE patients and CSF (n=53) and 
plasma (n=50) from 58 controls were analyzed for presence of JCV DNA. Paired CSF and 
plasma samples were obtained from 49 of the NPSLE patients and 44 of the control patients. 
Sixty-three of the NPSLE patients had ongoing treatment with immunomodulatory 
medication at the time of sampling. Five NPSLE patients were treatment-naïve and eight of 
the patients had no immunomodulatory treatment at the time of sampling but had been treated 
with prior to sampling.  
We did not find any CSF or plasma samples positive for JCV, in either patients or 
controls. All NPSLE patients were followed up clinically, after sampling, for a mean of 5.4 
years (range 3-8) and none of them developed clinical signs of PML. Six SLE patients died 
during the follow-up time period; causes of death were cerebral vasculitis and pneumonia, 
CNS demyelination and pneumonia, cortical dementia, depression and cognitive impairment, 
ischemic heart disease and cerebrovascular disease. 
In conclusion, our study could not confirm occurrence of JCV DNA in a cohort of 
SLE patients treated with several immunosuppressive medications from a Swedish hospital-
based SLE cohort. However, considering the knowledge of possible reactivation of JCV for 
all the patients undergoing immunosuppressive therapies, clinicians should be observant for 
new clinical signs or symptoms from the CNS. The clinical, radiological evaluation, serology 
-and/or CSF JCV analyses should be performed as a standard. 
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5.3. PAPER III 
In this study 56 patients were finally diagnosed with ischemic stroke, 13 cases of the original  
69 were excluded due to history of hemorrhagic stroke, insufficient information for 
neuroimaging to fulfill the TOAST classification or insufficient genotype information after 
collection. These patients were diagnosed with SLE fulfilling at least four of the ACR criteria 
at a mean age of 34 (range 11-76) years and 91 % were female. The mean age at the time of 
the first stroke was 52 years (range 18-84). According to stroke subtypes distribution 
occurred 12% LAA, 21% CE, 16% SAO, 33% OE/APS and 16% UE. Patients with ischemic 
stroke of OE/APS or CE represented 31 of the 56 cases (55%).  Patients with OE/APS-
associated strokes were significantly younger than other stroke subtypes (median age 42 vs. 
59 years) p=0.003. Strokes of OE/APS and CE origin, but not other stroke subtypes, were 
associated with the STAT4 risk genotype. HLA-DRB1 alleles were not related to stroke 
subtype.  
A high proportion (45%) of all patients with ischemic stroke in this study were 
positive for at least one of the investigated aPL. Before inclusion into the genetic studies 
venous thromboembolic disease occurred in 32%, IHD in 18% and ischemic peripheral 
vascular disease in 18% of patients with ischemic stroke. A further 28% suffered from heart 
valve affection and half of them had valve prosthesis. 
In conclusion, our study confirms several previous studies, which have demonstrated 
that aPL/APS plays an important role for ischemic heart and cerebrovascular disease in SLE. 
The incidence of ischemic stroke is two-to three-fold among enhanced among SLE patients 
as compared to the general population and the relative risk is more increased among younger 
SLE patients < 50 years. In our study the APS/OE sub-group had median age of 42 years, and 
patients with heart valve disease were common. Another interesting finding was the 
association of STAT4 genotype to ischemic stroke in both APS/OE and CE subtypes.  
There are limitations with our study as it has a retrospective design and a relatively 
small size with only Swedish Caucasians participants. Some patients were excluded due to 
lack of genetic data and due to insufficient information to make the classification according 
to TOAST subclasses. Nevertheless, based on our findings we suggest that all SLE patients 
should be thoroughly investigated at diagnosis for aPL and further investigations with 
echocardiography should be performed to detect cardiac/heart valve risk factors for ischemic 
stroke. 
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5.4. PAPER IV 
Epilepsy and/or seizures have been reported to occur in variable proportions of SLE patients 
ranging from 3%-64%, due to differences in study population and methodology. Our study 
based in a hospital SLE cohort included a totally of 440 patients. At the start of the study 
14% of patients in the cohort had died and 2.7% were lost to follow-up of other reasons, 
resulting in the questionnaire being sent to 368 patients, of which 312 (85%) responded. Of 
these, 42% screened positive. Thirty-six SLE patients (11.5%) fulfilled the ILAE criteria for 
epilepsy, which is more common than in the general Swedish population (0.7%). Mean age at 
seizure onset was 32 years (range 1-84) and the mean age at SLE diagnosis was 36 years 
(range 11-67), four of these were males (11%).  
The finding that seizures were of focal onset in 83% is notable, differing from 
previous studies of SLE population. Almost all of these patients 35/36 screened positively in 
the WHO questionnaire, one patient developed epilepsy during our data collection. Eight of 
these 36 patients (22%) overlapped with SLE diagnosis. Sixteen (44%) had onset before SLE 
diagnosis and 12 patients had their first seizure after SLE diagnosis. Manifestations of 
NPSLE occurred in 50%. Cerebrovascular disease was more than twice as common 
(p=0.001) and psychosis increased three-fold (p=0.0006) in NPSLE patients with epilepsy 
versus NPSLE patients without epilepsy. APS was more common in patients with epilepsy 
compared to epilepsy-free SLE patients with or without NPSLE (p=0.02). In 50% of patients 
with epilepsy no other etiology than SLE, was detected. 
In conclusion we report an 11.5% prevalence of epilepsy in a large and well-
characterized hospital-based SLE cohort, the majority of our patients being classified with 
focal epilepsy. APS was more common in patients with epilepsy compared to epilepsy-free 
SLE patients with or without NPSLE (p=0.02). Cerebrovascular disease was highly 
significantly more common. In 50% of patients with epilepsy no other etiology than SLE, 
was detected.                                         
The power of our study from the start was the direct communication with our patients 
regarding the questionnaire. We could identify all possible cases with seizures and proceed to 
a structured interview and clinical investigation. We noticed the difference in establishing an 
epilepsy diagnosis. According the 11 ACE classification criteria for SLE, the patients also 
fulfilled one of the basic criteria due to the seizure. Several of these patients with one 
unprovoked seizure continued with further epileptic activity and mostly with focal seizures 
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that qualified for epilepsy diagnosis. Our study provides additional support that 
immunological mechanisms are important for the pathogenesis of epilepsy. 
A limitation of this study is that it is retrospective design and that SLE patients were 
identified in hospital-based registries that might lead to generalized conclusions for SLE and 
epilepsy. However, the Rheumatology Departments in our study are referral centers for SLE 
patients, a population base of approximately 1.2 million inhabitants, thus representing a large 
population.  
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6.  GENERAL DISCUSSION  
The studies in this thesis are based on the carefully diagnosed SLE patients attending the in 
Rheumatology Clinic at Karolinska University Hospital with suspected actual or earlier 
neurological manifestations and/or psychiatric and/or cognitive symptoms or impairments. 
Neuropsychiatric symptoms in SLE are diverse, nineteen case definition being published in 
1999 (11), as earlier discussed in these thesis, including both central and peripheral 
involvement. This is probably not the complete catalogue, for example posterior reversible 
encephalopathy syndrome (PRES) is reported to med more common in SLE patients. Two 
NPSLE manifestations are included in the ACR criteria for SLE diagnosis, namely epilepsy 
or psychosis. It is obvious that involvement of the nervous system is an important feature of 
SLE, and it is thereby also important to better diagnose and understand how this systemic 
disease affects the nervous system. 
The search for informative biomarkers relating to diagnosis, disease activity or treatment 
responses have been intense for a number of years. A large number of markers relating to 
different pathways have been suggested, but very few have been replicated and validated.  
There are limitations in our studies, namely a small size for power and due to 
heterogeneous neurological manifestations difficulties in making comparisons i.e. with acute 
and chronic neurological clinical cases. We should also have included SLE patients without 
neurological manifestations as controls. Every patient was indeed carefully diagnosed, 
investigated both by a rheumatologist and a neurologist. The preferred outcome of our studies 
should, however, be to provide better information for the clinician, to assist them in making a 
better diagnostic work-up and better informed knowledge about patient treatment options.  
Our second study aimed to assess the presence and viral load of JC polyomavirus 
DNA in cerebrospinal fluid and plasma from NPSLE patients compared with controls. Our 
negative findings considering JCV DNA in CSF or in peripheral blood in samples for all 
these patients treated with several immune suppressive medications and controls were 
encouraging. Seventy-one SLE patients with well-documented immunosuppressive 
medications were included in this study. One may ask if the methods we used to detect the 
levels of JCV DNA were sensitive enough to answer the question of probable risk for the 
future reactivation of JCV, leading to PML.  All of these laboratory methods are continuously 
improved and actual levels for measurement should be followed at the time of each individual 
investigation for suspected JC virus involvement in CNS. The previous systematic literature 
33 
 
review by Henegar et al. (130) refers to larger population-based observational studies 
regarding the risk of PML in SLE patients versus non-SLE patients, treated with similar 
immunosuppressive medicals used for SLE management. These indicate that PML is a very 
rare disease in SLE with the incidence range (1.0-2.4) per 100 000 person years and suggests 
that there appears to be an increased risk of PML associated with SLE in the general 
population. Due to the knowledge of PML, often with lethal outcome, this risk should be 
studied further when treating our patients with any of these immunosuppressive 
pharmaceuticals.  
The third study included a total of 665 patients from three leading centers for SLE 
research and we could determine ischemic stroke in 56 of 69 suspected cases. Information for 
classification of subtypes of stroke according to TOAST was based on available medical 
records and the evaluators for were blinded for genotypes of the patients. In some cases lack 
of information and difficulties in obtaining original brain images to confirm the findings in 
some suggested cases caused exclusion of patients, leading to smaller size and lower power 
for our study.  
The results of our previous studies on association with STAT4 and HLA-DRB1 risk 
genotypes to both aPL and to vascular disease indicated an enhanced risk of vascular events 
(44). We aimed to investigate these risk alleles among ischemic stroke subtypes compared 
with controls. Our study demonstrates that more than half of the ischemic strokes were 
associated with OE/APS or CE origin. Patients with APS-related stroke were younger. 
Compared to the prospective study by Mikdashi et al. (131), they had a different view of the 
relations between APS and anti-cardiolipin. The lack of formal APS diagnosis in one study, 
ethnicity and culture may explain the discrepancy.  Our study has limitations. It is 
retrospective in design and all participants were European Caucasians, which may obstruct 
the general applicability. 
In the fourth study, we determined the prevalence of epilepsy in our SLE cohort. We 
report prevalence of epilepsy of 11.5%, a much higher level in SLE as compared to the 
population at large. Our methodology, using the screening questionnaire, enabled us to 
collect a large number of patients with suspected seizures, with a high number completing the 
questionnaire. Combining individual structured interviews and medical chart reviews we 
could confirm or discard a diagnosis of epilepsy according to ILEA criteria (108-110), 
exclude acute symptomatic seizures (109) and also define a possible presence of other 
NPSLE manifestations (11). Concomitant conditions unrelated to SLE were investigated. 
Autoantibody levels and LA were determined. The majority of the patients with epilepsy had 
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focal seizures (83%), in contrast to a prior study by Appenzeller et al. (73) who reported 
generalized seizures for the great majority (88%) as well as González-Duarte et al. who 
reported tonic-clonic seizures in 77%. The large study by Hanly et al. (132, 133) reported 
60% as primary generalized and 31% as focal. These three studies were all prospective with 
another kind of study design, with various times of follow-up. Our study has a retrospective 
design and the patients were identified in hospital-based registries which might explain the 
differences.  However, these patients were well-characterized, many patients being followed-
up for many years at the Rheumatology Departments. Information from medical records was 
available together with patients fulfilling the questionnaire and clinical evidence of recurred 
unprovoked seizures. We could determine the type of epilepsy and count the prevalence in 
this cohort. Our data suggest a multifactorial background to epilepsy with association with 
cerebrovascular disease, psychosis and APS. 
 
6.1. FUTURE DIRECTIONS 
 
One of the main focuses in this thesis was to provide deeper understanding of NPSLE 
symptoms and draw to conclusions that might improve the clinical care of this patients, as 
well as indicating ideas for both short- and long-term evaluation of these patients.  
The following options could benefit this purpose. 
 A standardized protocol should be created and used for prospective follow-up 
both for clinical use and for possible future studies, including MRI 
investigation for NPSLE patients, and a fatigue scale – for each patients 
repetitively and  for to use interactively in the waiting room. In addition, an EP 
screening questionnaire for patients with a history of suspected seizures 
 CSF investigations – for patients with a new NP manifestation, or in relapses 
of CNS symptoms including the latest items for detecting of more specific 
changes in the intrathecal compartment.  
 SLE patients with positive aPL and/or those with APS should be observed 
attentively for CVL risks 
 Investigate SLE patients early with echocardiography to detect possible 
cardiological risk factors for neurological complications 
 Include the investigation of JCV serology as a routine analyses for SLE 
patients treated with immunosuppressive medicine, as a baseline 
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 To provide more resources for neuropsychological assessments and 
counselling 
 Include the patients with NPSLE syndromes not only in national SLE register 
in Sweden, but also as an subgroup in the Neuro register in Sweden to benefit 
further research of autoimmune diseases that influence CNS or/and co-operate 
at a national level to get a better evidence and power for studies and 
conclusions. 
 Continue with further studies in NPSLE and select one syndrome at a time as 
focus for each study instead of lumping all NPSLE syndromes together. 
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7.  CONCLUSIONS 
 
● APRIL protein levels in CSF from NPSLE patients were significantly higher 
compared to levels in CSF from OND patients 
● Fatigue correlated to higher APRIL levels in CSF of NPSLE patients 
● All CSF and plasma samples from both NPSLE patients and controls investigated 
were negative for JCV DNA 
● Occurrence of JCV  DNA was not common in the blood and CSF among patients with 
NPSLE patients receiving immunomodulatory treatments 
● Swedish SLE patients with ischemic stroke mainly had an etiology classified as due to 
other determined category (OE) such as presence of APS or due to cardio-embolic 
origin (CE) according to the TOAST classification. 
● These two subtypes of stroke were associated to the STAT4 genotype. 
● Patients with APS-associated stroke were younger than non-APS stroke patients. 
● The validated epilepsy prevalence was 11.5% in a large and well-characterized 
hospital-based SLE cohort and a majority of the cases could be classified as focal 
epilepsy. Cerebrovascular disease and APS were associated with epilepsy. 
 
The overall evaluation and the result of our clinical studies is that SLE is a multifactorial and 
serious systemic disease that involves both the central and peripheral nervous system with 
heterogeneous manifestations. Immunological, vascular, hematological, and cardiovascular 
and brain lesions due several etiologies contribute to the occurrence of different neurological 
symptoms. Based on our findings we suggest that all SLE patients with neurological 
manifestations such as CVL and epilepsy should be thoroughly investigated at diagnosis for 
aPL, echocardiographic investigation should be performed to detect risk factors for ischemic 
stroke, and brain imaging and CSF analysis should be a standard. 
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